1 / 5

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer NEJM January 3, 2008

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer NEJM January 3, 2008. Authors: David Cunningham et al Date posted: April 3, 2008. Treatment A: ECF Epirubicin 50 mg/m2 IV q 3 weeks Cisplatin 60 mg/m2 IV q 3 weeks 5-FU 200 mg/m2 per day continuous infusion. Treatment B: ECX

laura-kane
Download Presentation

Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer NEJM January 3, 2008

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Capecitabine and Oxaliplatin for Advanced Esophagogastric CancerNEJM January 3, 2008 Authors: David Cunningham et al Date posted: April 3, 2008

  2. Treatment A: ECF Epirubicin 50 mg/m2 IV q 3 weeks Cisplatin 60 mg/m2 IV q 3 weeks 5-FU 200 mg/m2 per day continuous infusion Treatment B: ECX Epirubicin 50 mg/m2 IV q 3 weeks Cisplatin 60 mg/m2 IV q 3 weeks Capecitabine 625 mg/m2 bid continously R Treatment C: EOF Epirubicin 50 mg/m2 IV q 3 weeks Oxaliplatin 130 mg/m2 IV q 3 weeks 5-FU 200 mg/m2 per day continuous infusion • 1002 patients • locally advanced (inoperable) or metastatic (80%) cancer esophagus, GE junction,gastric • - Adenocarcinoma, squamous cell, or undiff. carcinoma • - 2x2 non-inferiority design • - Primary Enpoint: non • inferiority in OS Treatment D: EOX Epirubicin 50 mg/m2 IV q 3 weeks Oxaliplatin 130 mg/m2 IV q 3 weeks Capecitabine 625 mg/m2 bid continously

  3. RESULTS • Patients • 85-90% in all groups were adenocarcinoma • Relatively even distribution among: esophagus, GE junction, stomach

  4. STUDY COMMENTARY • This large RCT demonstrated non-inferiority for 5-FU/capecitabine and cisplatin/oxaliplatin when given with epirubicin in patients with advanced esophagogastric cancer. • In planned survival analysis among 4 groups, survival in EOX group was improved compared to ECF (HR 0.80, 95%CI 0.66-0.97 – Median Survival improved from 9.9 to 11.2 mos). • No significant difference in overall toxicity or QOL between the 4 arms. • Oxaliplatin had more grade 3-4 diarrhea and neuropathy than cisplatin but less neutropenia and alopecia • greater grade 3-4 neutropenia (but no higher rates of febrile neutropenia) and HFS (10% vs 4%) in ECX group versus ECF • High rate of thromboembolism 11.4% overall • rate was significantly greater in cisplatin group compared to oxaliplatin group (15.% vs 7.6%, P<0.001).

  5. BOTTOM LINE FOR CANADIAN MEDICAL ONCOLOGISTS • In many Canadian centres the standard of care for this patient population is ECF. This study shows that capecitabine can be safely substituted for infusional 5-FU in patients with advanced esophagogastric cancer. • This provides a treatment option for patients which is free of pumps and venous access devices – the only downside being slightly higher rates of Gr 3/4 HFS. • The use of oxaliplatin avoids the requirement of IV hydration used with cisplatin and there is a signal of improved efficacy with this agent. However, the overall toxicity and QOL was not improved with the substitution of oxaliplatin for cisplatin. • Given the greater ease of delivery it is likely that EOX and/or ECX will emerge in the future as preferred standards compared to ECF but access to oxaliplatin and capecitabine for advanced gastric cancer will likely depend on funding of these agents in most parts of Canada.

More Related